NASDAQ:BCAX Bicara Therapeutics Q2 2025 Earnings Report $22.64 +0.05 (+0.22%) Closing price 04:00 PM EasternExtended Trading$22.65 +0.01 (+0.04%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Bicara Therapeutics EPS ResultsActual EPS-$0.50Consensus EPS -$0.54Beat/MissBeat by +$0.04One Year Ago EPSN/ABicara Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABicara Therapeutics Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateTuesday, August 12, 2025Conference Call Time8:00AM ETUpcoming EarningsBicara Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Bicara Therapeutics Earnings HeadlinesBicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 17 at 3:47 AM | americanbankingnews.comBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.September 18 at 1:00 AM | Stansberry Research (Ad)Bicara Therapeutics Secures Boston Headquarters Through SubleaseAugust 25, 2026 | tipranks.comBicara Therapeutics’ Earnings Call Signals Pivotal ProgressAugust 23, 2026 | tipranks.comCan Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite OverhaulAugust 19, 2026 | finance.yahoo.comSee More Bicara Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email. Email Address About Bicara TherapeuticsBicara Therapeutics (NASDAQ:BCAX), Inc. is a clinical-stage biotechnology company focused on developing treatments for solid tumors. The company uses a proprietary bifunctional antibody platform designed to target tumor cells while modifying the surrounding tumor microenvironment, which may help improve the activity of cancer immunotherapies. Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to block epidermal growth factor receptor (EGFR) signaling and inhibit transforming growth factor beta (TGF-β), two pathways associated with tumor growth and immune suppression. Bicara is evaluating ficerafusp alfa in combination with other therapies, including pembrolizumab, for patients with recurrent or metastatic head and neck squamous cell carcinoma and other solid tumors. Founded in 2020 and headquartered in Cambridge, Massachusetts, Bicara conducts clinical development activities primarily in the United States. The company became publicly traded on the Nasdaq under the symbol BCAX in 2024. Its pipeline and research programs are focused on expanding the use of bifunctional therapies across additional solid-tumor indications.View Bicara Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
